# Patent

## Title
miRNA triplex formations for the downregulation of viral replication

## Abstract

As discovered herein, using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the downregulation and/or inhibition of viral replication.

## Background
PRIORITY
The instant application claims the benefit in U.S. Provisional Application Ser. No. 61/137,744 filed Aug. 1, 2008, the entire contents of which are incorporated by reference herein.


BACKGROUND OF THE INVENTION
1) Field of the Invention
The present invention relates to miRNA triplex formations capable of downregulating viral replication. More particularly, the present invention relates to the discovery of miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, and the use of such mutually homologous miRNAs to form stable triplex molecules effective in the downregulation and/or inhibition of viral replication.
2) Description of Related Art
The general concept of harnessing RNA interference to silence gene replication/transcription/expression for therapeutic benefit is known in the art, as is the idea of using single-stranded interfering RNA molecules (e.g., antisense RNA, small interfering RNA (siRNA), microRNAs (miRNA)) to silence expression of viral genes, for example, as part of a component in an antiviral therapy. Further efforts in the prior art to control viral replication include the use of attenuated viral mutants or viral sequences, subunits or particles that can be used to generate a protective immune response against live virus (i.e., viral particles that are sufficiently “virus” looking to stimulate host immune system to generate protective antibodies but sufficiently disabled or incomplete to prevent onset of negative viral effects). Also, considerable attention has been directed towards the use of proteins, peptides or chemicals having therapeutic antiviral potential that operate by inhibiting an essential viral activity in vivo, acting on the virus itself to forestall/inhibit/prevent its negative consequences. None of these efforts involve the use of stable triplex formations to inhibit viral replication; rather, they utilize completely different mechanisms. Further, the prior art is replete with other efforts directed towards the use of viral sequences having utility in the context of the construction of viral vectors for the delivery of genes or proteins of interest (i.e., in the context of gene therapy) or in the context of a vaccine adjuvant.
For example, U.S. Pat. No. 6,682,907 describes the use of triplex structure DNA in transferring nucleotide sequences. The structure of the DNA triplex formed during reverse transcription in this process enables, or at least contributes, to the entry of the retroviral genome into the cell nucleus, thus allowing infection of non mitotic cells. The invention concerns a nucleotide sequence of retroviral or retroviral-like origin, which can be prepared synthetically, comprising cPPT and CTS regions which are cis-acting in reverse transcription in general, and in particular two associated polynucleotides when they are placed in the normal retroviral genome, each polynucleotide containing at least 10 nucleotides. The vector of the invention contains a transgene inserted under the control of viral or non viral sequences regulating transcription or expression. Ultimately, the triplex formation with HIV in this invention is intended to promote an immune response in the body, and does not disclose specific sequences that effect HIV replication by forming stable triplexes in vivo.
U.S. Pat. No. 6,555,342 describes a fusion protein delivery system and uses thereof. Ultimately, this invention demonstrated that Vpr and Vpx can serve as vehicles to deliver functionally active enzymes to the HIV virion, including those that may exert an antiviral activity such as SN. However, there is no discussion of using the specific miRNA or siRNA sequences identified in the present invention to form stable triplexes to inhibit HIV replication.
U.S. Pat. No. 6,531,123 describes lentiviral vectors and contemplates attenuated lentiviruses, and improved viral packaging and transducing vectors derived from lentiviruses, especially HIV-1, useful for the delivery of nonlentiviral genes to target cells. It also contemplates the use of these vectors in delivering transgenes to target cells, especially nondividing cells, in organisms, especially humans. However, there is no discussion of using the specific miRNA or siRNA sequences identified in the present invention to form stable triplexes to inhibit HIV replication.
U.S. Patent No. 20070099858 describes small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against influenza virus gene expression. However, there is no disclosure of using miRNA to form triplex formation to inhibit the HIV.
U.S. Patent No. 20030175693 describes an HIV recombinant vaccine. The invention encompasses recombinant HIV and SIV viruses containing heterologous transcriptional regulatory elements in the U3 region of the virus. In particular embodiments, the recombinant virus has decreased replication in vivo and the virus has a protective effect when administered to a host. The recombinant virus can have heterologous transcriptional regulatory elements that replace the HIV region corresponding to the NFKB/Sp1/TATA Box/initiation region (−114 to +1) or corresponding to the NFKB/Sp1/TAR region (−114 to +93) of the SIVmac239 long terminal repeat. However, there is no disclosure of using miRNA to form triplex formation to inhibit the HIV.
In each instance, the prior art fails to teach the use of specific miRNA sequences such as those identified in the instant application to form stable triplexes with HIV to inhibit HIV replication in accordance with the teachings of the present invention. Thus, although the present invention arises in view of the noted background, it nevertheless diverges therefrom in the discovery of specific miRNA sequences capable of forming with the HIV-1 genome stable triplexes that inhibit HIV-1 replication in vivo. These miRNA sequences find utility in the context of pharmaceutical compositions for use in the treatment and prevention of the HIV, and given the conserved nature of many viral genomes, may be reasonably extended to the treatment of other viruses, particularly retroviruses, more particularly lentiviruses such as SIV etc.
Accordingly, it is an object of the present invention to provide mutually homologous miRNAs give rise to the creation of stable triplex formations with a viral genome, such as the HIV-1 genome, to effect the downregulation of viral replication in vivo.
SUMMARY OF THE INVENTION
The above objective is accomplished according to the present invention by providing an isolated nucleic acid molecule selected from the group consisting of: (a) a nucleotide sequence selected from among SEQ ID NOs: 1273-1372; (b) a nucleotide sequence consisting of the complement of a nucleotide sequence of (a); and (c) a nucleotide sequence consisting of 15-25 nucleotides having a sequence identity of at least 90% to a nucleotide sequence of (a) or (b).
In a further embodiment, the nucleic acid molecule is (a) a nucleotide sequence selected from among SEQ ID NOs: 1289-1290, 1309-1310, 1317-1318, and 1337-1338; (b) a nucleotide sequence consisting of the complement of a nucleotide sequence of (a); or (c) a nucleotide sequence consisting of 15-25 nucleotides having a sequence identity of at least 90% to a nucleotide sequence of (a) or (b).
In a further embodiment, the nucleic acid molecule is selected from the group consisting of RNA, DNA and modified nucleotide molecules.
In a further embodiment, the nucleic acid molecule is single-stranded.
In a further embodiment, the nucleic acid molecule is at least partially double-stranded.
In a further embodiment, the nucleic acid molecule is an miRNA.
In a further embodiment, the nucleic acid molecule is an siRNA.
In a further embodiment, the nucleic acid molecule comprises at least one modified nucleotide. Preferably, nucleotide is a 2′ modified nucleotide.
In a further embodiment, the nucleotide sequence of (c) has an identity of at least 95% to a nucleotide sequence of (a) or (b).
In a further embodiment, the nucleotide sequence in part (c) further comprises a uridine (U) or adenosine (A).
In a further embodiment, the nucleotide sequence of (c) consists of 19-25 nucleotides.
In a further embodiment, the nucleotide sequence of (c) consists of 21-23 nucleotides.
The above objective is further accomplished according to the present invention by providing a recombinant expression vector comprising the nucleic acid molecule expressed above.
The above objective is further accomplished according to the present invention by providing a composition comprising at least one nucleic acid molecule as expressed above in combination with a pharmaceutically acceptable carrier.
In a further embodiment, the pharmaceutically acceptable carrier is suitable for diagnostic applications.
In a further embodiment, the pharmaceutically acceptable carrier is suitable for therapeutic applications.
The above objective is further accomplished according to the present invention by providing a method of inhibiting replication of a virus in a target cell, said method comprising the steps of: (a) introducing into a target cell infected with the virus an homologous small double stranded RNA comprising a nucleic acid molecule as set forth above and (b) allowing the homologous small double stranded RNA to hybridize with the viral genome.
In a further embodiment, the hybridization of step (b) results in the formation of a stable triplex molecule.
In a further embodiment, the homologous small double stranded RNA is contained within a recombinant vector.
In a further embodiment, the virus is one of a retrovirus, lentivirus, HIV, HIV-1, and HERV.
In a further embodiment, the viral genome comprises a proviral or preintegration version of the virus.
The above objective is further accomplished according to the present invention by providing a method of reducing the level of HIV-1 replication in a target cell, said method comprising the steps of: (a) introducing into a target cell infected with the virus an homologous small double stranded RNA at least 80% complementary to a portion of the HIV-1 genome, the homologous small double stranded RNA comprising a nucleic acid molecule as set forth in claims 1 or 2; and (b) allowing the homologous small double stranded RNA to hybridize with the HIV-1 genome or a proviral or preintegration version thereof.
In a further embodiment, the hybridization of step (b) results in the formation of a stable triplex molecule.
In a further embodiment, the homologous small double stranded RNA is an miRNA or an siRNA.
In a further embodiment, the target cell is in vitro.
In a further embodiment, the target cell is in vivo.
In a further embodiment, the method comprises administering a recombinant vector carrying the homologous small double stranded RNA to a subject comprising said target cell.
In a further embodiment, the method comprises treating said subject for an HIV-1 mediated disease condition.
The above objective is further accomplished according to the present invention by providing a method of inhibiting replication of a virus in a cell comprising the steps of: (a) stimulating the expression of an endogenous antisense sequence comprising a nucleotide sequence as set forth in claims 1 or 2 and (b) inducing the endogenous miRNA to hybridize with the viral genome.
In a further embodiment, the endogenous antisense sequence comprises a primary miRNA transcript.
In a further embodiment, the endogenous antisense sequence comprises a stem loop pre-miRNA transcript. In a further embodiment, the viral genome comprises a proviral or preintegration version of the virus.
It will be understood by those skilled in the art that one or more aspects of this invention can meet certain objectives, while one or more other aspects can meet certain other objectives. Each objective may not apply equally, in all its respects, to every aspect of this invention. As such, the preceding objects can be viewed in the alternative with respect to any one aspect of this invention. These and other objects and features of the invention will become more fully apparent when the following detailed description is read in conjunction with the accompanying figures and examples. However, it is to be understood that both the foregoing summary of the invention and the following detailed description are of a preferred embodiment and not restrictive of the invention or other alternate embodiments of the invention. In particular, while the invention is described herein with reference to a number of specific embodiments, it will be appreciated that the description is illustrative of the invention and is not constructed as limiting of the invention. Various modifications and applications may occur to those who are skilled in the art, without departing from the spirit and the scope of the invention, as described by the appended claims. Likewise, other objects, features, benefits and advantages of the present invention will be apparent from this summary and certain embodiments described below, and will be readily apparent to those skilled in the art. Such objects, features, benefits and advantages will be apparent from the above in conjunction with the accompanying examples, data, figures and all reasonable inferences to be drawn therefrom, alone or with consideration of the references incorporated herein.



BRIEF DESCRIPTION OF THE DRAWINGS
The construction designed to carry out the invention will hereinafter be described, together with other features thereof. The invention will be more readily understood from a reading of the following specification and by reference to the accompanying drawings forming a part thereof, wherein an example of the invention is shown and wherein:
FIG. 1 shows sequences of the HIV-1 duplexes and third strand homologous oligonucleotides (representing one strand of homologous small RNA). FIG. 1 discloses SEQ ID NOS 1373-1384, respectively, in order of appearance;
FIG. 2 shows fluorescence melting profiles for sequence numbers 1-4 in FIG. 1. FIG. 2 discloses SEQ ID NOS 1385-1404, respectively, in order of appearance from left to right;
FIG. 3 shows inhibition of HIV-1 over time in stably transfected miRNA expressing cell lines;
FIG. 4 shows the effects of HIV-1 homologous miRNA on viral replication; and,
FIGS. 5A-5D show photos of stably transfected HeLa-CD4+ cell lines exhibiting triplex formations.



DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT
With reference to the Figures, the invention will now be described in more detail. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the preferred methods and materials are now described. However, it is to be understood that this invention is not limited to the particular molecules, compositions, methodologies or protocols herein described, as these may vary in accordance with routine experimentation and optimization. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. However, in case of conflict, the present specification, including definitions, will control. Accordingly, in the context of the present invention, the following definitions apply:
Definitions:
As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to a “molecule” is a reference to one or more molecules and equivalents thereof known to those skilled in the art, and so forth.
As used herein, the term “organism” refers to any living entity composed of at least one cell. A living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal, including a human being.
As used herein, the term “biological sample” refers to a whole organism or a subset of its tissues, cells or component parts (e.g., body fluids, including but not limited to blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid and semen). The term “biological sample” further refers to a homogenate, lysate, extract, cell culture or tissue culture prepared from a whole organism or a subset of its cells, tissues or component parts, or a fraction or portion thereof. Lastly, “biological sample” refers to a medium, such as a nutrient broth or gel in which an organism has been propagated, which contains cellular components, such as proteins or polynucleotides.
As used herein, the term “tissue” refers to biological tissues, generally defined as a collection of interconnected cells that perform a similar function within an organism. Four basic types of tissue are found in the bodies of all animals, including the human body and lower multicellular organisms such as insects, including epithelium, connective tissue, muscle tissue, and nervous tissue. These tissues make up all the organs, structures and other body contents.
The terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is a modified residue, or a non-naturally occurring residue, such as an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
The terms “polynucleotides”, “oligonucleotides” “nucleotides”, “nucleic acids”, and “nucleic acid molecules” are used interchangeably herein to refer to a polymer of nucleic acid residues linked by ester bonding, and, unless otherwise specifically indicated, are similarly to the amino acids referred to by their commonly accepted single-letter codes (triple codon system). Similar to the amino acids, they encompass both naturally-occurring and non-naturally occurring nucleic acid polymers. The polynucleotide or oligonucleotide may be composed of DNA, RNA or a combination thereof.
In the context of the present invention, nucleic acid homology is deemed “substantially identical” where they have between about 70% and about 80% or more preferably, between about 81% and about 90%, or even more preferably, between about 91% and about 99%, sequence identity along their entirety.
The term “isolated” is used herein to refer to a molecule separated from its native environment (i.e., in a non-naturally occurring form). The term “purified” is used herein to refer to a molecule in a form substantially free from contaminants.
The present invention relates to inhibitory molecules that are complementary to a nucleotide sequence within a viral genome, particularly the HIV-1 genome. The inhibitory molecules of the present invention act by binding to/hybridizing with the viral genome to form a stable triplex (or multiplex) therewith, thereby inhibiting the replication of the genome and the subsequent transcription and/or translation of the genes contained therein. As such, the inhibitory molecules of the present invention find utility in the treatment and prevention of viral infection, particularly HIV-1 infection. An inhibitory molecule of the present invention can be directly or indirectly introduced into a subject, into a tissue or cell thereof, in a form that is capable of binding to the viral genome. Alternatively, it can be carried in a vector.
The term “inhibitory molecules” as used herein encompasses both nucleotides that are entirely complementary to the target sequence and those having a mismatch of one or more nucleotides, so long as the inhibitory molecules can specifically hybridize to the target sequences of the viral genome. The inhibitory molecules of the present invention include oligonucleotides that have a sequence identity of at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or higher over a span of at least 10 continuous nucleotides. Algorithms known in the art can be used to determine the sequence identity. The inhibitory molecules of present invention include modified oligonucleotides. For example, thioated oligonucleotides can be used to confer nuclease resistance to an oligonucleotide.
The inhibitory molecules of the present invention are preferably directed against the HIV-1 genome. However, given the high degree of sequence conservation among retroviruses, such inhibitory molecules may also find utility in connection with other of viruses, more particularly retroviruses including Human endogenous retroviruses (HERVs), more particularly lentiviruses, examples of which include, but not limited to, FIV (feline immunodeficiency virus), SIV (simian immunodeficiency virus), HIV-1, and HIV-2.
The inhibitory molecules of the present invention may contain one or more modified nucleotides and/or non-phosphodiester linkages. Chemical modifications well known in the art are capable of increasing stability, availability, and/or cell uptake of the double-stranded molecule. The skilled person will be aware of other types of chemical modification which may be incorporated into the present molecules (WO03/070744; WO2005/045037). In one embodiment, modifications can be used to provide improved resistance to degradation or improved uptake. Examples of such modifications include phosphorothioate linkages, 2′-O-methyl ribonucleotides (especially on the sense strand of a double-stranded molecule), 2′-deoxy-fluoro ribonucleotides, 2′-deoxy ribonucleotides, “universal base” nucleotides, 5′-C-methyl nucleotides, and inverted deoxyabasic residue incorporation (US20060122137).
In another embodiment, modifications can be used to enhance the stability or to increase targeting efficiency of the inhibitory molecule. Modifications include chemical cross linking between two complementary strands of a double-stranded molecule, chemical modification of a 3′ or 5′ terminus of a strand of a double-stranded molecule, sugar modifications, nucleobase modifications and/or backbone modifications, 2-fluoro modified ribonucleotides and 2′-deoxy ribonucleotides (WO2004/029212). In another embodiment, modifications can be used to increased or decreased affinity for the complementary nucleotides in the target sequence and/or in the complementary molecule strand (WO2005/044976). For example, an unmodified pyrimidine nucleotide can be substituted for a 2-thio, 5-alkynyl, 5-methyl, or 5-propynyl pyrimidine. Additionally, an unmodified purine can be substituted with a 7-deza, 7-alkyi, or 7-alkenyi purine. In another embodiment, when the double-stranded molecule is a double-stranded molecule with a 3′ overhang, the 3′-terminal nucleotide overhanging nucleotides may be replaced by deoxyribonucleotides (Elbashir S M et al., Genes Dev Jan. 15, 2001 15(2): 188-200). For further details, published documents such as US20060234970 are available. The present invention is not limited to these examples and any known chemical modifications may be employed for the double-stranded molecules of the present invention so long as the resulting molecule retains the ability to bind to the viral genome and inhibit replication thereof.
As used herein, the term “siRNA”, also known as small interfering RNA (siRNA), short interfering RNA or silencing RNA, refers to a class of inhibitory molecules that are typically 20-25 nucleotide-long double stranded RNA molecules that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway where the siRNA interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g. as an antiviral mechanism or in shaping the chromatin structure of a genome.
As used herein, the term “miRNA”, also known as microRNA, refers to double-stranded RNA molecules, typically of about 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes that are transcribed from DNA but not translated into protein (non-coding RNA); instead they are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression.
As noted above, the inhibitory molecules of the present invention are capable of binding to viral genome sequences, forming a stable triplex (or multiplex) therewith so as to inhibit replication thereof. This binding results from hybridization of complementary sequences. Nucleic acid hybridization is affected by conditions such as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of about 30° C., typically in excess of about 37° C., and preferably in excess of about 45° C. Stringent salt conditions will ordinarily be less than about 1,000 mM, typically less than about 500 mM, and preferably less than about 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. (See e.g., Wetmur & Davidson, 1968). Determining appropriate hybridization conditions to identify and/or isolate sequences containing high levels of identity is well known in the art. (See e.g., Sambrook et al., 1989). Representative moderate stringency conditions comprise, for example, hybridization at 50° C. and in 10×SSC (0.9 M NaCl/0.09 M sodium citrate), wherein the hybridized nucleic acid molecules remain bound when subjected to washing at 55° C. in 1×SSC. Sequence identity can be further determined by hybridization under more stringent conditions, for example, at 50° C. or higher and 0.1×SSC (9 mM mM sodium citrate), as described below. Typically, under “stringent conditions” a probe will hybridize specifically to its target sequence, but to no other sequences.
For the purposes of specifying conditions of high stringency, preferred conditions are salt concentration of about 200 mM and temperature of about 45° C. One example of such stringent conditions is hybridization at 4×SSC, at 65° C., followed by a washing in 0.1×SSC at 65° C. for one hour. Another representative stringent hybridization scheme uses 50% formamide, 4×SSC at 42° C. As used herein, the term “stringent conditions” can also mean conditions of high stringency, for example 6×SSC, 0.2% polyvinylpyrrolidone, 0.2% Ficoll, 0.2% bovine serum albumin, 0.1% sodium dodecyl sulfate, 100 μg/mL salmon sperm DNA and 15% formamide at 68° C.
Pharmaceutical Formulations:
The inhibitory molecules of the present invention may serve as drugs themselves or candidates for the development of drugs that inhibit the replication of HIV-1 and can be applied to the treatment or prevention of HIV-1 and other viral disorders.
When administrating one or more inhibitory molecules of the present invention as a pharmaceutical composition for humans and other mammals, including without limitation, mice, rats, hamsters, guinea-pigs, rabbits, cats, dogs, sheep, pigs, cattle, monkeys, baboons, and chimpanzees, the isolated molecules can be directly administered, either singly or in a cocktail combination, or can be formulated into a dosage form using known pharmaceutical preparation methods. For example, according to the needs of the patient, the inhibitory molecules of the present invention can be made into an external preparation, for example, a liniment or a poultice, by admixing it with a suitable base material which is inactive against the nucleic acid. Alternatively, the inhibitory molecules of the present invention or pharmaceutical formulations thereof can be taken orally, such as in the form of sugar-coated tablets, capsules, elixirs and microcapsules, or non-orally, such as in the form of injections of sterile solutions or suspensions with water or any other pharmaceutically acceptable liquid. Likewise, the molecules can be mixed with pharmaceutically acceptable carriers or media, specifically, sterilized water, physiological saline, plant-oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binders, and such, in a unit dose form required for generally accepted drug implementation. The amount of active ingredient contained in such a preparation makes a suitable dosage within the indicated range acquirable.
Also, as needed, the inhibitory molecules of the present invention can be formulated into tablets, powders, granules, capsules, liposome capsules, injections, solutions, nose-drops and freeze-drying agents by adding excipients, isotonic agents, solubilizers, stabilizers, preservatives, pain-killers, and such. These can be prepared by conventional methods.
The inhibitory molecules of the present invention can be given to the patient by direct application onto the ailing site or by injection into a blood vessel so that it will reach the site of ailment. In addition, a molecule-mounting medium can also be used to increase durability and membrane-permeability. Examples include, but are not limited to, liposomes, poly-L-lysine, lipids, cholesterol, lipofectin or derivatives of these.
Examples of additives that can be admixed into tablets and capsules include, but are not limited to, binders, including gelatin, corn starch, tragacanth gum and arabic gum; excipients, including crystalline cellulose; swelling agents, including corn starch, gelatin and alginic acid; lubricants, including magnesium stearate; sweeteners, including sucrose, lactose or saccharin; and flavoring agents, including peppermint, spearmint, Gaultheria adenothrix oil and cherry. When the unit-dose form is a capsule, a liquid carrier, including an oil, can be further included in the above ingredients. Sterile composites for injection can be formulated following normal drug implementations using vehicles, for example, distilled water or saline solution, suitable for injection.
Physiological saline, glucose, and other isotonic liquids, including adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, can be used as aqueous solutions for injection. These can be used in conjunction with suitable solubilizers, for example, alcohols including ethanol; polyalcohols, including propylene glycol and polyethylene glycol; and non-ionic surfactants, including Polysorbate 80 (TM) and HCO-50.
Sesame oil or soy-bean oil can be used as an oleaginous liquid, can be used in conjunction with benzyl benzoate or benzyl alcohol as a solubilizer, and can be formulated with a buffer, including phosphate buffer and sodium acetate buffer; a pain-killer, including procaine hydrochloride; a stabilizer, including benzyl alcohol and phenol; and/or an anti-oxidant. A prepared injection can be filled into a suitable ampoule.
Methods well known to those skilled in the art can be used to administer the molecules and pharmaceutical compositions of the present invention to patients, for example as an intra-arterial, intravenous, or percutaneous injection or as an intranasal, transbronchial, intramuscular or oral administration. When the active agent is a nucleic acid or encodable by a nucleic acid (as is the case herein), the nucleic acid molecule can be inserted into a vector for gene therapy and the vector administered to a patient to perform the therapy. In either context, the dosage and method of administration may vary according to the body-weight, age, and symptoms of the patient; however, one skilled in the art can suitably adjust the requisite dosage according to the patient's condition using routine optimization procedures.
For example, although the dose of inhibitory molecule needed to bind to a target viral genome, form a stable triplex therewith, and subsequently inhibit replication thereof depends on a number of factors, the dose is generally about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult human (weighing about 60 kg).
When administering a molecule or pharmaceutical composition of the present invention parenterally, in the form of an injection to a normal adult human (weighing about 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day. In the case of other animals, the appropriate dosage amount can be routinely calculated by converting to 60 kg of body-weight.
Hereinafter, the present invention is described in more detail by reference to the Examples detailed herein below. However, the following materials, methods and examples only illustrate aspects of the invention and in no way are intended to limit the scope of the present invention. As such, methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
Analysis and Examples:
Human immunodeficiency virus type 1 (HIV-1) infection is often accompanied by co-infection with other pathogens that generally result in accelerating the progression of the disease and in early development of AIDS1. However, sometimes certain co-infections can have beneficial effects2-6. Several reports have documented the beneficial effects of two genetically related human herpes viruses-HHV-6, HHV-7- and GBV-C (a Hepatitis C virus related virus that is non-pathogenic but belongs to Flavivirus family) co-infections in HIV-1-infected individuals in terms of significantly longer survival and better prognosis7. However, some reports have contradicted such findings with the result that this issue remains controversial9-10. During the course of viral infections viruses from similar species compete with each other to gain access to the host replication machinery, causing one type of virus to eventually block the entry of the competing virus into the host cell by receptor modulation or by intracellular interference in its replication inside the cell by various mechanisms10. On the other hand, viruses from heterologous species can co-infect cells cooperatively where one virus provides another with a useful protein that it co-opts for its own use11. Rarely, one type of virus becomes dependent on another virus. One such example is hepatitis Delta, which requires the presence of hepatitis B virus in order to replicate. Viruses also interact with each other directly at molecular levels10.
In order to evaluate the intracellular mechanisms at molecular levels of the reported beneficial effects of HHV-6,-7 and GBV-C viruses it was considered that such effects might be caused by the activation of mutually homologous endogenous miRNAs that can interfere with replication of both types of viruses (i.e. HIV-1 and co-infecting HHV-6A/B, or HHV-7 or GBV-C). In recent years, miRNAs have been shown to block replication of various pathogenic viruses in plants, warms and eukaryotic organisms12-14. The discovery of virally encoded miRNAs has attracted immense attention towards the possibility of miRNA as a critical modulator of viral pathogenecity and host susceptibility in higher eukaryotes13-15 When eukaryotic cells encounter double-stranded miRNA, transcripts of homologous mRNAs are silenced through RNA interference12-14 or triplex forming complexes (TF) between the nucleic acids16-17.
There is growing evidence to support the concept that miRNAs of the vertebrate host may regulate the viral life cycle, viral tropism, and the pathogenesis of viral diseases11-14,16-18. For example, human miR-32 has been shown to have a direct negative effect on the replication of the retrovirus primate foamy virus type 1 (PFV-1) by downregulating the replication-essential viral proteins encoded by open reading frame 2 (ORF2)19. As the evolutionary process would dictate, pathogenic viruses have also evolved numerous countering mechanisms that can neutralize the host miRNA-based defenses17,20.
In recent years, several reports have documented a better prognosis for HIV-1-infected patients co-infected with HHV-6, HHV-7 or GBV-C who may live three times longer as compared to those without these co-infections. Recent studies have also identified anti-viral roles of host microRNAs (miRNAs) in plants, worms, and mammals.
In order to evaluate whether the apparent beneficial effects of the co-infecting viruses are due to mutually homologous miRNAs, a computational analysis was done of miRNAs that have significant homologies to both HIV-1 and the co-infecting viruses. Constructs of such miRNAs were obtained and introduced into Hela-CD4+ cells to give rise to the development of stably transfected cell lines each expressing a particular miRNA.
As detailed herein below, it was determined that 50 miRNAs showed >80% homology to HIV-1 and, among these, 11 mutually targeted co-infecting viruses. As a result, 12 miRNAs were synthesized, 11 with significant mutual homologies and one with no homology to co-infecting viruses but with >90% homology to HIV-1 alone. Further, miRNAs were selected for their ability to form triplexes using a tool that detects C+·GC and T.AT triplets, factors suggested in the art to impart greater stability between miRNA and HIV-1 provirus. The stability of such miRNA triplexes was measured in vitro. In addition, triplex-forming miRNAs were detected using triplex specific monoclonal antibodies. Next, stably transfected Hela-CD4+cell lines were developed expressing each of the miRNAs utilizing pSuper vector. Referring to Table 1, all 12 miRNAs exhibited a significant inhibition of HIV-1 (P>0.001) as measured by HIV-1p24 ELISA and Real Time PCR (>90%; p>0.001) as compared to mock transfected control. Accordingly, the present invention provides a new miRNA-based therapeutic strategy for HIV-1 using a molecular mechanism by which the co-infecting viruses impart resistance to HIV-1.
In developing the present invention, it was hypothesized that since HHV-6, HHV-7 and GBV-C are non-pathogenic viruses, a co-infection with these viruses might activate miRNA-based antiviral immunity12,17. Since a single miRNA can share homology to several targets, it is theoretically possible that the co-infecting viruses are activating protective miRNAs that are mutually homologous with HIV-1 and quelling their replications in uninfected target cells making them resistant to HIV-1 infection. Of note, all three co-infecting viruses primarily infect CD4+ T-lymphocytes it is possible that they are interfering with HIV-1 replication3,5,7.
Therefore, Homo sapiens miRNAs were first computationally analyzed for possible homologies to all four viral genomes by utilizing the Sanger miRNA Database21. This identified several miRNAs that have significant (>70%) sequence homologies with HHV-6 (A and B types), HHV-7 and GBV-C and HIV-1 (Tables 1-3). Fifty miRNAs showed >80% homology to HIV-1 sequences (Table 4). Currently, Sanger human miRNAs database contains 733 miRNAs (has-miRs). After tabulating all the miRNAs that target the two most common HIV-1 strains (accessions #s:NC—001722 and AF033819), HHV-6 (NC—001664 and NC—000898), HHV-7 (NC—001716) and GBV-C (NC—001710), all the miRNA that share significant mutual homologies to HIV-1 (>60%) were again tabulated. Table 1 shows selected sequences of miRNAs sequence alignments from the miRNAs that demonstrate homology to HIV-1 and exhibited significant to HHV-6, HHV-7 and GBV-C viruses (see all the sequences in Table 4).
In order to explore the molecular mechanisms of the observed protective roles of these co-infecting viruses via miRNA, a mathematical algorithm was developed to identify the miRNAs that would form stable nucleic acid complexes with HIV-124,28. Previously, it was hypothesized that some of the relatively high sequence homologous miRNAs may develop stable triplexes forming complexes (TF) with HIV-116,17. Recent evidence supports the notion that some miRNAs may mediate the silencing by TF24. Roberts and Crothers22 have shown that C+·GC and T.AT triplets impart a greater triplex stability. Several investigators have confirmed this observation and have demonstrated that the most stable triplexes contain alternating C+·GC and T·AT triplets22-23. Two main structural motifs have been defined in which the third strand runs either parallel or antiparallel to the duplex purine strand. Antiparallel triplexes contain G·GC, A·AT and T·AT triplets while parallel triplexes contain C+·GC and T·AT triplets.
It was reasoned that the presence of mutually homologous miRNAs, as naturally occurring phenomenon, provides for the formation of intermolecular triplexes and offers a unique opportunity for targeting HIV-1 proviral sequences by miRNAs. This has the potential for use in anti-HIV-1 therapy17. DNA triple helices are formed by the binding of synthetic oligonucleotides within the major groove of duplex DNA, where they make specific hydrogen bond interactions with groups on the exposed faces of the purine bases. Based on these reports and several experimental data that C+·GC and T·AT triplets motifs favor TF, a java-based tool was developed that can predict the third strand sequence, representing miRNA, that can form the stable triplex with duplex DNA sequences16,17 representing HIV-1 provirus. The tool was utilized to determine if any of the 50 miRNAs that exhibited >80% homologies to HIV-1 and the other beneficial co-infecting viruses sequences could be candidate for TF31.
As shown in Table 4, 11/50 sequences made good candidates for TF on the basis of the algorithm that looks for C+·GC+T·AT triplet motifs and multiple alignment with more than one co-infecting viruses2-6,31. Triplex Stability Index or TSI is shown for all 50 miRNAs (highlighted in dark for C+·GC and light for T·AT in Table 4). According to this data, 12 miRNAs were determined to be good candidates since they exhibited  ̃40% TSI. In addition to the TSI, consideration was given to the length of the homologous pairing (RNAi silencing requires at least 19 base pairs) and to the mutual homologies to the three co-infecting viruses (Table 1). Therefore, twelve candidate miRNAs were selected and listed in Table 1. Eleven miRNAs exhibited strong TF capability (35-52% TSI as shown in Table 1) but also showed significant homologies to one or more of the three co-infecting viruses (62-84%), the 12th one (hsa-miR-659) showed homologies to laboratory strains of HIV-1 only (pNL4.3, 42% TSI).
In order to measure the stabilities of the miRNA, four sets of representative sequences for TF were utilized, oligonucleotides were synthesized that represented four of ten miRNAs (FIG. 1) and dsDNA HIV-1 proviral sequences. In order to avoid any potential problems with misannealing, intramolecular duplexes were used in which the two strands were connected by a single hexaethylene glycol moiety (H). The intramolecular duplexes and their respective third strand oligonucleotides are shown in FIG. 1. This arrangement of fluorophore and quencher allowed us to increase the amount of the third strand without affecting the total fluorescence signal. The 20 mer sequences were chosen so as to generate triplexes with different arrangements of C+·GC and T·AT triplets and are based around repeats of (CCT)n, (CT)n, (CTT)n and Tn as described previously22-23.
Fluorescence melting profiles were determined using an MJ Research Chromo4 Real Time thermocycler with minor modifications23. The logic of this experiment is such that when a triplex is formed, the fluorophore and quencher are in close proximity and the fluorescence is quenched. Upon heating the triplex complex denatures, the fluorophore and quencher are separated and there is a large increase in fluorescence that is recorded by the scanning imaging system. Triplexes were prepared in 50 mmol L−1 sodium acetate pH 5.0 containing 150 mmol L−1 NaCl. Each sample (20 μl) contained 0.25 μmol L−1 duplex DNA and 0.25 μmol L−1 triplex-forming oligonucleotide, as described previously23. The complexes were denatured by heating to 95° C. at a rate of 0.1° C. s−1 and maintained at this temperature for 5 min before cooling to 20° C. at 0.1° C. s−1. Samples were then held at 20° C. for 10 min before melting again by heating to 95° C. at 0.1° C. s−1. The fluorescence was recorded during both melting and annealing phases. The thermocycler excited the samples at 495 nm and measured the emission at 520 nm. Since this technique measures the changes in fluorescence that accompany the denaturation process of the fluorophore and quencher, the signal was most strongly affected by opening of the terminal Hoogsteen pairs rather than dissociation of the entire third strand. The FITC-labeled duplex strands were used as standards in each experimental variable. As shown in FIG. 2, under these conditions all four miRNAs formed stable TF and exhibited Tm values of 82° C., 77° C., 62° C., and 53° C., respectively.
After establishing TF stabilities of four out of ten representative miRNAs, the potential anti-HIV-1 activities of all ten TF miRNAs in HeLa-CD4+ cell lines were tested. Twelve pSUPER-derived vectors (pSuper.neo.gfp24,28) designed to drive expression of each of the miRNAs sequences constructed hairpin (hp) sequences that upon transcription expressed specific miRNAs shown in Table 1. pSuper hairpin constructs were generated by annealing together DNA primers encoding the entire hairpin and ligating the double-stranded fragments directly into BgIll-HindIll-digested pSUPER. Twelve different shmiRNA constructs as shown in Table 1 were generated. The recombinant pSuper vectors were confirmed by restriction enzyme digestion by BgIll-HindIll. The correct samples were sequenced on ABI PRISM 3031 sequencer.
In order to determine the anti-HIV-1 activities of the vectors in vitro, stably transfected HeLa-CD4+ cell lines (NIH AIDS Research & Reagent Program; Cat #1022) were generated in selection media as described previously25-26. After four weeks of selection the resistant populations were characterized by observing under UV-Fluorescent microscope for green fluorescent cells (gfp) as well as PCR analyses (data not shown). As controls, nontransfected cells and cells transfected with the same plasmid backbone but without miRNA sequence was used (designated ΔNC: 30). The protective effects of each of the miRNAs and the backbone vector were evaluated by infecting each of the cell lines. Untransfected Hela-C4+ cell lines were used as controls. All cell lines were infected separately with HIV-1 NL-4-3 at a multiplicity of infection of 0.1 of cell-free viral stocks using the pNL4-3 isolates or cell lines were mock infected and then harvested 6, 12, 24, 48 days post-infection25-26. Filtered supernatants were used for HIV-1 p24 ELISA. Total RNA was harvested with TRIzol for the Real Time PCR for singly-spiced HIV-1 RNA25-26. As shown in FIG. 3 upon infection all cell lines expressing human miRNAs showed significant resistant to HIV-1 (p>0.001) and infection was reduced from  ̃60% to >80% in cell lines stably expressing miRNAs six days post infection. There were variations in the degree of inhibitions between days of harvests post infection, however, it was >60% in most cases except in miRNA-548-b and miRNA-574-3 where it was 53% and 42%, respectively on day 48 post infection. The p24 ELISA data were further confirmed by measuring the singly-spliced HIV-1 mRNA (FIG. 4).
In order to further determine if the observed HIV-1 inhibition is due to triplex formation (TF), two mAbs were utilized that can recognized TFs27-28. In all cases stably transfected HeLa-CD4+ cell lines exhibited clear evidence of TFs. Representative photographs are shown in FIGS. 5A-5D.
Methods:
Human microRNAs mature sequences were downloaded from the human mi RBase Sequences database (http://microrna.sanger.ac.uk/sequences/: (as of 28 Jan. 2008:20). Before analyses all the U of miRNAs were converted to T. For querying potential targets in the HIV-1, HHV-6A, HHV-6B, and GBV-C genomes we downloaded the full coding sequences of all four viruses (HIV-1 strains accession#s:NC—001722 and AF033819; HHV-6 accession # s: NC—001664 and NC—000898, HHV-7 accession # NC—001716 and GBV-C accession #NC—001710). The RefSeq validated reference sequences (http://ncbi.nlm.nih.gov) and the six representative strain sequences as identified by the International Committee on Taxonomy of Viruses (ICTV) (http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_retro.htm) were utilized. Three well-established web links where used (http://microrna.sanger.ac.uk/, http://hiv-web.lanl.gov/content/hiv-db/mainpage.html, and http://www.ebi.ac.uk/) to predict homology for the 733 Homo sapiens microRNAs obtained from the miRBase Sequences, microRNA Registry. Sequence homologies of 733 Homo sapiens miRNAs versus HHV-6, -7 and GBV-C target genomes was explored using the local sequence alignment algorithms offered on the following well-established web sites: http://microrna.sanger.ac.uk/, http://hiv-web.lanl.gov/content/hiv-db/mainpage.html, and http://www.ebi.ac.uk/.
Oligodeoxyribonucleotides (Odn):
HPLC purified Odn were purchased from Sigma Genosys (The Woodlands, Tex., US). Fluorophore (flourescein isothiocyanate: FITC) was incorporated at 5′-end of the duplex DNA using FITC-cap-dU and the black-hole quencher-1 (BHQ-1) was attached at the 5′ end of the third strand oligonucleotide as previously described22-23. In order to avoid any potential problems with misannealing, intramolecular duplexes were used in which the two strands were connected by a single hexaethylene glycol moiety (H) (FIG. 1). This arrangement of fluorophore and quencher allowed us to increase the amount of third strand without affecting the total fluorescence signal. The 20 mer sequences were chosen so as to generate triplexes with different arrangements of C+·GC and T·AT triplets and are based around repeats of (CCT)n, (CT)n, (CTT)n and Tn as described previously22-23.
Fluorescence Melting Curves of Intermolecular Triplexes:
Fluorescence melting profiles were determined using an MJ Research Chromo4 Real Time Thermocycler with minor modifications as set forth above and previously described23. The fluorescence was recorded during both melting and annealing phases. The thermocycler excited the samples at 495 nm and measured the emission at 520 nm. Since this technique measures the changes in fluorescence that accompany Denaturation process of the fluorophore and quencher, the signal was most strongly affected by opening of the terminal Hoogsteen pairs rather than dissociation of the entire third strand. However, simple separation of the termini leaves the fluorescent groups in close proximity, and dissociation of the entire third strand is a highly cooperative process. With this basic assumption, the fluorescence profiles provided a good approximation for the dissociation of the third strand. Tm values were determined from the first derivatives of the melting profiles using the MJR Chrmo4 software and were reproducible to within 0.2° C. Unless otherwise stated, the Tm values quoted refer to the second melting transition. The FITC-labelled duplex strands were used as standards in each experimental variable.
Designing and Construction of miRNA Expression Vector:
pSUPER-derived vectors (pSuper.gfp.neo24,30) designed to drive expression of each of the twelve miRNAs sequences in Table 1. The miRNA against HIV-1 was selected using the software available from OligoEngine. These sequences were arranged in the 64 base pair oligonucleotide in the form: BgIll site/19 bp Sense Strand/9 bp Stuffer/19 bp Antisense strand/Stuffer. A sequence exactly complementary to the 64 bp sequence was also obtained which had Hind Ill site at its terminal end. These two oligonucleotides were annealed to form a duplex oligonucleotide carrying BgIll and HindIll sites at their terminal sites for cloning into the pSuper Retro vector. The annealed oligonucleotide was cloned into the BgIll/HindIll sites of pSuper retro vector. Positive clones were confirmed by sequencing on ABI PRISM 3031 sequencer as well as by restriction enzyme digestion by BgIll-HindIll. Thirteen different shmiRNA constructs were generated, 12 expressed respective duplex miRNA and one was used as control that contained empty vector without miRNA (Table 1). Each oligonucleotide is placed downstream of H1 promoter's TATA box and it generates a duplex miRNA which is predicted to form a stem-loop precursor transcript which is then cleaved in the cell to produce a functional mature 20-21 bp miRNA.
Intracellular Expression of shmiRNAs:
HeLa-C4+ cell line (NIH AIDS Research & Reagent Program; Cat #1022) were used to develop stably transfection cell lines. The cells were cultured in RPMI-1640 supplemented with 10% fetal calf serum and penicillin-streptomycin (100units/ml). The transfection were carried out when cells were  ̃70% confluent at 1.106 cells per 25 mL flask. Cells were transfected with each of the pSuper vectors, separately, by use of lipofectamine (Invitrogen) with a total of 50 ng of DNA per flask in serum-free RPMI-1640. 48 hours post-transfection, the medium was changed to neomycin-containing medium (100 units/ml) for selection. After 4 weeks in selection, resistant cell populations and clones were characterized. As controls, non-transfected cells and cells transfected with the same vector backbone but without the 64 bp miRNA hp was utilized (designated as C).
HIV-1 Infection Experiments:
Initial studies were conducted using the HIV-1 strain pNL4-3. Viral stock was prepared as described previously25-26. Infections of the HeLa-CD4+ lines with HIV-1 were performed by incubating equivalent of 1,000 ng of cell-free viral stocks with the various cell lines for 12 hrs at 37° C. After incubation the cell were washed 6 time with serum free medium to remove extracellular virions and then cells were cultures in complete medium for 5-days and supernatants were analyzed for the amount of HIV-1 p24 by ELISA assay. Cells were harvested at the same time and after multiple washes by centrifugations, cell pallets were used for total RNA isolated.
Indirect Immunofluorescence:
HeLa-CD4 cells were examined for triplex formation (TF) by utilizing two murine monoclonal antibodies (mAbs), Jel 318 and Jel 46627. mAbs were mixed in equal volume, at 2 μg/mL. These anti-triplex mAbs can recognize triplexes between any combinations of DNAs and RNAs, but more strongly between dsDNA and ssRNA27-28. A fluorescent conjugated secondary antibody for mouse antibody was used for staining triplexes25.
Quantitative Real Time PCR:
Total RNA was extracted using Qiagen RNeasy Total RNA isolation kit with DNase I treatment to ensure complete removal of residual DNA. RNA was quantified in the NanoDrop 1000 Spectrophotometer (3.1.0 software, NanoDrop Technologies Inc. IScript cDNA synthesis kit (Biorad) was used to perform the reverse transcriptase reaction, 100 ng of total RNA was used in the cDNA synthesis reaction. QRT-PCR was performed using SYBR®GREEN PCR Master Mix and a Chromo4TM System (Bio-Rad Laboratories, Hercules, Calif.). Each PCR reaction consisted of 5.0 μL of 5.0 ng of cDNA, 1.0 μL of 200 nM each of the respective primers (forward and reverse primers: 12.5 μL of SYBR®GREEN and 5.5 μL of nuclease free water. The following primers were used, Forward: 5′-CTCTCGACGCAGGACTCGGC-3′ (SEQ ID NO: 1), Reverse, 5′-CCTTCCCCCTGGCCTTAACCG-3′29 (SEQ ID NO: 2). 1:10 dilution of the cDNA synthesis reaction was used in the real time PCR for mRNA expression analysis. The following program: Amplification was carried out as follows: one cycle of 10 min at 95° C. (hot-start PCR) followed by 40 cycles in three steps each (95° C. for 15 sec, 60° C. for 1 minute, 72° C. for 45 sec) and one cycle of 10 min at 72° C. Melting temperature analysis was performed by slow increase in temperature (0.2° C./2 sec) from 45° C.-95° C. Standard curves for unspliced was performed using serial dilutions derived from DNA of pNL4-3 (80, 40, 20, 10, 5.0, 2.5, 1.25, 0.625, 0.3125 and 0.156 ng/μL). All samples were assayed in triplicates.
Data Analysis:
The significance of differences in relative gene expression numbers Ct(Ct((Cyclo)-Ct(target gene)) measured by real time quantitative PCR was calculated using a two-tailed Student's t test. Probability values less than 0.05 were considered significant27.
Accordingly, a new method has been devised that mimics processes in co-infected individuals which explain the apparent beneficial effects. Evaluation of the regulatory effects of miRNAs on viral replication by analyzing the mutually homologous miRNAs-first by gene alignment tool and then by evaluating their effect in vitro by stably transfected cell lines, results in highly effective anti-HIV-1 miRNA based therapies.
All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.
While a preferred embodiment of the invention has been described using specific terms, such description is for illustrative purposes only, and it is to be understood that changes and variations may be made without departing from the spirit or scope of the following claims. Through routine experimentation, one skilled in the art will readily recognize that various changes and modifications can be made therein without departing from the spirit and scope of the invention. Other advantages and features will become apparent from the claims filed hereafter, with the scope of such claims to be determined by their reasonable equivalents, as would be understood by those skilled in the art. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.
REFERENCES


    1. Karp, C L, Auwaerter, P. G. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial and viral pathogens. Clin Infect Dis. 2007; 45:1214-20.
    2. Lisco, A. Grivel J C, Biancotto A, et al. Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol. 2007; 81:708-17
    3. Frenkel, N, Schirmer E C, Wyatt L S et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc. Natl. Acad. Sci. USA 1990; 87:748-752
    4. Lusso P, Secchiero P, Crowley R W, Garzino-Demo A, Berneman Z N, Gallo R C. CD4 is a critical component of the receptor for human herpesvirus 7: Interference with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1994; 91:3872-3876.
    5. Glushakova, S., Baibakov, B., Margolis, L. B. & Zimmerberg, J. Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat. Med. 1995; 1:1320-1322.
    6. Gimenez-Barcons M, Ribera M, Llano A, Clotet B, Este J A, Martinez M A. et al. Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection. Clin Infect Dis. 2005; 40:1342-9.
    7. Xiang J, Wünschmann S, Diekema D J, Klinzman D, Patrick K D, George S L, Stapleton J T. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med. 2001; 345:707-14.
    8. Ryt-Hansen, R., Katzenstein, T. L., Gerstoft, J. & Eugen-Olsen, J. No influence of GB virus C on disease progression in a Danish cohort of HIV-infected men. AIDS Res Hum Retroviruses. 2006; 22:496-8.
    9. Vignoli, M., Furlini, G., Re, M. C., Ramazzotti, E. & La Placa, M. Modulation of CD4, CXCR-4 and CCR-5 makes human hematopoietic progenitor cell lines infected with human herpesvirus-6 susceptible to human immunodeficiency virus type 1. J Hematother Stem Cell Res. 2000; 9:39-45.
    10. Taylor, J. M. Hepatitis delta virus. Virology. 2006; 344:71-6.
    11. Matzke, M. A., Mette, M. F. & Matzke, A. J. Transgene silencing by the host genome defense: Implications for the evolution of epigenetic control mechanisms in plants and vertebrates. Plant Mol Biol. 2000; 43:401-15.
    12. Jose, A. M, & Hunter, C. P. Transport of Sequence-Specific RNA Interference Information Between Cells. Annual Review of Genetics 2007; 41:305-330.
    13. Kidwell, M. G. & Lisch, D. R. Perspective: transposable elements, parasitic DNA and genome evolution. Evolution Int J Org Evolution 2001; 55:1-24.
    14. Taganov, K. D., Boldin, M. P. & Baltimore, D. MicroRNAs and immunity: Tiny players in a big field. Immunity 2007; 2:133-7
    15. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297
    16. Bagasra, O, Stir A E, Pirisi-Creek L, Creek K E, Bagasra Au, and Lee J. Role of miRNAs in regulation of lentiviral latency and persistence. Applied Immunochem and Molecular Morphology 2006; 14:166-90.
    17. Bagasra, O. A unified concept of HIV-1 Latency. Expert Opin Biol Ther 2006; 6:1135-1149.
    18. Hakim S T, Alsayari M, McLean D C et al. A large number of the primate MicroRNAs target lentiviruses, RE and endogenous retroviruses. BBRC 2008; 369:357-362.
    19. Lecellier C H, Dunoyer P, Arar K et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005; 308:557-560
    20. Cullen, B. R. Viruses and microRNAs. Nat. Genet. 38, pp. 2006; S25-S30
    21. Griffiths-Jones S, Saini H K, van Dongen S, Enright A J Nucleic Acids Res 2008; 236 (Database Issue):D154-D158
    22. Roberts, R. W. & Crothers, D. M. Prediction of the stability of DNA triplexes. Proc Natl Acad Sci USA 1996; 93:4320-5
    23. James, P. L., Brown, T. & Fox, K. R. Thermodynamic and kinetic stability of intermolecular triple helices containing different proportions of C+*GC and T*AT triplets. Nucleic Acids Res. 2003; 3:5598-606
    24. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript Nature 2007; 445:666-670.
    25. Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz R J. Targeting of HIV-1 Reverse Transcriptase by Intracellular Expression of Single-Chain Variable Fragments (SFv) to Inhibit Early Stage of HIV-1 Replication. J. Virology 1996; 170:3392-4300.
    26. Bagasra, O., K. Khalili, Seshamma, T., Taylor, J. P. & Pomerantz, R. J. Tar-Independent Replication of HIV-1 in Glial Cells. J Virology 1992; 66:7522-7528.
    27. Agazie Y M, Burkholder G D, Lee J S. Triplex DNA in the nucleus: direct binding of triplex specific antibodies and their effect on transcription, replication and cell growth. Biochem J. 1996; 316: 461-466.
    28. Raghavan S C, Chastain P, Lee J S, Hegde B G, Houston S, Langen R, Hsieh C L, Haworth I S, Lieber M R. Evidence for a triplex DNA conformation at the bcl-2 major breakpoint region of the t(14; 18) translocation. J Biol Chem. 2005; 280:22749-60.
    29. Seshamma, T., Bagasra, O., Trono, D., Baltimore, D., Pomerantz, R. J. Blocked Early-Stage Latency in the Peripheral Blood Cells of Certain HIV-1-Infected Individuals. Proc Natl Acad Sci USA 1992; 89:10663-10667.
    30. Krom Y D, Fallaux F J, Que I, Lowik C, van Dijk K W. Efficient in vivo knock-down of estrogen receptor alpha: Application of recombinant adenovirus vectors for delivery of short hairpin RNA. BMC Biotechnol. 2006; 6:11
    31. Mahalingam K., O Bagasra. Bioinformatics Tools: Searching for Markers in DNA/RNA Sequences. Biocomp. Vol II {g 612-615. Proceedings of Computer Science Computer Engineering and Applied Computing” Jul. 14-21 2008.
    32. Marmor, M, K. Hertzmark, S. M. Thomas, P. N. Halkitis, and M. Vogler. Resistance to HIV Infection. J Urban Health. 2006; 83(1): 5-17
    33. Hattori J, Okumura N, Yamazaki Y, Uchiyama M, Hamaguchi M, Nishiyama Y, Kaneda T. Beneficial effect of GB virus C co-infection in Human Immunodeficiency Virus type 1-infected individuals. Microbiol Immunol. 2007; 51:193-200.
    34. Grivel J C, Ito Y, Faga G et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat. Med. 2001; 7:1232-1235.
    35. Saayman S, Barichievy S, Capovilla A, Morris K V, Arbuthnot P, Weinberg M S. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoSONE. 2008; 2; 3:e2602.


Tables:







TABLE 1







Human miRNA showing mutual homologies (>80%) with HIV


clone pNL 4-3 & co-infecting viruses GBV-C (>70%),


HHV-6 (>80%) and HHV-7 (>70%)

















Proportion &






SEQ

Triplex





Homo-
ID

Stability




No
logy
NOS:
Sequence Alignment
Index
Common
Target

















1
89.5
 3  4




 8/19
42%
HHV-6A (94.0) HHV-6B (89.5) HHV-7 (86.7)
pNL (nef) HHV-6A (U34) HHV-6B (U34) HHV-7 (U7)


 


2
85.7
 5  6




 9/21
42%
HHV-6A (88.9) HHV-6B (80.0) HHV-7 (77.8)
pNL (pol) HHV-6B (U7) HHV-7 (U57)


 


3
86.4
 7  8




 9/22
40%
GBV-C (77.3) HHV-6A (85.0) HHV-6B (80.0)
pNL (env) HHV-6A (U39)


 


4
80.0
 9 10




10/20
50%
GBV-C (73.7) HHV-6B (80.0)
pNL (pol) GBV-C (gp1) HHV-6B (U85)


 


5
91.3
11 12




12/23
52%
HHV-7 (76.0)
pNL (tat) HHV-7 (U20)


 


6
82.6
13 14




11/23
47%
GBV-C (77.8) HHV-7 (100) HHV-6B (81.0)
pNL (gag) GBV-C (gp1) HHV-7 (U82)


 


7
85.0
15 16




 9/20
45%
HHV-7 (70.8)
pNL (env) HHV-7 (U7)


 


8
80.0
17 18




 0/20
 0%
HHV-7 (88.2)
pNL (vif) HHV-7 (U58)


 


9
94.7
19 20




 7/19
36%
GBV-C (70.8) HHV-6A (62.1) HHV-6B (62.1) HHV-7 (84.2)
pNL (tat) HHV-6A (U42)


 


10
100.0
21 22




 8/20
40%
GBV-C (53.1) HHV-6B (69.6) HHV-7 (85.0)
GBV-C (gp1) HHV6B (U28) HHV-7 (U59)


 


11
95.0
23 24




 7/20
35%
GBV-C (77.3) HHV-7 (77.3)
GBV-C (gp1) HHV-7 (U57)


 


12
90.5
25 26




 9/21
42%
—
—
















TABLE 1A







Human miRNA Showing mutual Homologies (>=80%) with HHV-6A











Homo-
SEQ ID



No.
logy
NOS:
Sequence Alignment Result













 1
90.5
 27  28






 


 2
90.5
 29  30






 


 3
90.5
 31  32






 


 4
90.0
 33  34






 


 5
84.2
 35  36






 


 6
81.8
 37  38






 


 7
85.0
 39  40






 


 8
81.0
 41  42






 


 9
85.0
 43  44






 


10
89.5
 45  46






 


11
80.0
 47  48






 


12
84.2
 49  50






 


13
80.0
 51  52






 


14
83.3
 53  54






 


15
83.3
 55  56






 


16
84.2
 57  58






 


17
84.2
 59  60






 


18
82.6
 61  62






 


19
81.0
 63  64






 


20
80.0
 65  66






 


21
84.2
 67  68






 


22
85.0
 69  70






 


23
83.3
 71  72






 


 24*
88.9*
 73  74






 


25
80.0
 75  76






 


26
85.7
 77  78






 


27
80.0
 79  80






 


28
80.0
 81  82






 


29
81.8
 83  84






 


30
82.6
 85  86






 


31
81.0
 87  88






 


 32*
80.0*
 89  90






 


33
88.9
 91  92






 


 34*
80.0*
 93  94






 


35
80.0
 95  96






 


36
80.0
 97  98






 


37
83.3
 99 100






 


38
81.0
101 102






 


49
84.2
103 104






 


40
85.0
105 106






 


41
82.6
107 108






 


42
81.0
109 110






 


43
81.0
111 112






 


44
87.0
113 114






 


45
89.5
115 116






 


46
83.3
117 118






 


47
81.0
119 120






 


48
81.8
121 122






 


49
81.8
123 124






 


50
83.3
125 126






 


51
84.2
127 128






 


52
89.5
129 130






 


53
80.0
131 132






 


 54*
80.0*
133 134






 


55
85.0
135 136






 


56
83.3
137 138






 


57
82.6
139 140






 


58
81.8
141 142






 


59
84.2
143 144






 


60
82.6
145 146






 


61
83.3
147 148






 


62
88.9
149 150






 


63
81.0
151 152






 


64
85.0
153 154






 


65
80.0
155 156






 


66
81.0
157 158






 


67
81.8
159 160






 


68
82.6
161 162






 


69
81.0
163 164






 


70
85.0
165 166






 


71
81.8
167 168






 


72
81.0
169 170






 


73
80.0
171 172






 


74
85.0
173 174






 


75
81.0
175 176






 


76
84.2
177 178






 


77
85.0
179 180






 


78
81.0
181 182






 


79
85.0
183 184






 


80
80.0
185 186






 


81
83.3
187 188






 


82
83.3
189 190






 


83
88.9
191 192






 


84
81.0
193 194






 


85
85.0
195 196






 


86
81.8
197 198






 


87
81.0
199 200






 


 88*
82.6*
201 202






 


89
81.0
203 204






 


90
81.0
205 206






 


91
80.0
207 208






 


 92*
80.0*
209 210






 


93
84.2
211 212






 


94
85.0
213 214






 


95
80.0
215 216






 


96
84.2
217 218






 


97
85.0
219 220






 


98
84.2
221 222






 


99
80.0
223 224






 


100 
84.2
225 226






 


101 
81.8
227 228






 


102 
81.0
229 230






 


103 
80.0
231 232






 


104 
81.8
233 234






 


105 
83.3
235 236






 


106 
89.5
237 238






 


107 
84.2
239 240






 


108 
81.0
241 242






 


109 
81.0
243 244






 


110 
82.6
245 246






 


111 
81.0
247 248






 


112 
81.8
249 250






 


113 
85.7
251 252






 


114 
80.0
253 254






 


115 
85.0
255 256






 


116 
81.0
257 258






 


117 
81.0
259 260






 


118 
80.0
261 262






 


119 
85.0
263 264






 


120 
83.3
265 266






 


121 
84.2
267 268






 


122 
81.8
269 270






 


123 
81.0
271 272






 


124 
85.0
273 274






 


125 
80.0
275 276






 


126 
80.0
277 278






 


127 
81.8
279 280






 


128 
89.5
281 282






 


129 
84.2
283 284






 


130 
83.3
285 286






 


131 
81.8
287 288






 


132 
80.0
289 290






 


133 
80.0
291 292






 


134 
82.6
293 294






 


135 
81.0
295 296






 


136 
82.6
297 298






 


137 
85.7
299 300






 


138 
81.0
301 302






 


139 
81.0
303 304






 


140*
80.0*
305 306






 


141 
80.0
307 308






 


142 
83.3
309 310






 


143 
81.8
311 312






 


144 
81.0
313 314






 


145 
83.3
315 316






 


146 
81.0
317 318






 


147 
84.2
319 320






 


148 
85.0
321 322






 


149 
82.6
323 324






 


150 
81.0
325 326






 


151 
84.2
327 328






 


152 
89.5
329 330






 


153 
84.2
331 332






 


154 
81.0
333 334






 


155 
80.0
335 336






 


156 
80.0
337 338






 


157 
81.8
339 340






 


158 
80.0
341 342






 


159 
81.0
343 344






 


160 
83.3
345 346






 


161 
85.7
347 348






 


162 
82.6
349 350






 


163 
80.0
351 352






 


164 
82.6
353 354






 


165 
83.3
355 356






 


166 
83.3
357 358






 


167 
81.0
359 360






 


168 
81.0
361 362






 


169 
81.0
363 364






 


170 
80.0
365 366






 


171 
80.0
367 368






 


172 
81.8
369 370






 


173 
81.0
371 372






 


174 
84.2
373 374






 


175 
85.0
375 376






 


176 
82.6
377 378




















TABLE 1B













 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 






















TABLE 2













 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 








 






















TABLE 3







Human miRNA Showing mutual Homologies (>=80%) with GBV-C











%
SEQ ID



No.
Homology
NO:
Sequence Alignment Result













 1
84.2
1071   1072






 


 2
84.2
1073   1074






 


 3
84.2
1075   1076






 


 4
84.2
1077   1078






 


 5
82.4
1079   1080






 


 6*
78.9*
1081   1082






 


 7*
70.8*
1083   1084






 


 8
84.2
1085   1086






 


 9
83.3
1087   1088






 


10
81.8
1089   1090






 


11
85.0
1091   1092






 


12
85.0
1093   1094






 


13
80.0
1095   1096






 


14
80.0
1097   1098






 


15
83.3
1099   1100






 


16
83.3
1101   1102






 


17
81.0
1103   1104






 


 18*
77.3*
1105   1106






 


19
80.0
1107   1108






 


20
81.0
1109   1110






 


21
80.0
1111   1112






 


 22*
77.8*
1113   1114






 


23
80.0
1115   1116






 


 24*
77.3*
1117   1118






 


25
80.0
1119   1120






 


26
85.0
1121   1122






 


27
81.0
1123   1124






 


 28*
72.7*
1125   1126






 


29
75.0
1127   1128






 


30
81.0
1129   1130






 


31
81.8
1131   1132






 


32
80.0
1133   1134






 


33
76.2
1135   1136






 


34
80.0
1137   1138






 


35
81.8
1139   1140






 


36
83.3
1141   1142






 


37
83.3
1143   1144






 


38
81.0
1145   1146






 


49
80.0
1147   1148






 


40
83.3
1149   1150






 


41
81.0
1151   1152






 


42
81.0
1153   1154






 


 43*
76.2*
1155   1156






 


44
85.0
1157   1158






 


45
81.0
1159   1160






 


46
82.4
1161   1162






 


47
83.3
1163   1164






 


48
83.3
1165   1166






 


49
83.3
1167   1168






 


50
80.0
1169   1170






 


51
80.0
1171   1172




















TABLE 4







Human miRNA Showing mutual Homologies (>=80%) with HIV-1 and with one


or more co-infecting viruses (i.e., GBV-C (>=70%), HHV-6 (>=80%) and HHV-7 (>=70%)













%
SEQ

Common



No.
Homology
ID NO:
Sequence Alignment Result
With
Target















 1
80.0
1173   1174




HHV-7 (76.2)
HIV (gag, gag-pol) HHV (U60)


 


 2
80.0
1175   1176




HHV-7 (76.2)
HIV (gag, gag-pol) HHV (U60)


 


 3
80.0
1177   1178





HIV (gag, gag-pol)


 


 4
84.2
1179   1180




HHV-6A (94.0) HHV-6B (88.9) HHV-7 (77.3)
HIV (nef) HHV-6A (U34) HHV-6B (U34) HHV-7 (U86)


 


 5
80.0
1181   1182





HIV (gp160, env)


 


 6
82.6
1183   1184




HHV-7 (73.1)
HIV (gp160, env) HHV-7 (U58)


 


 7
81.8
1185   1186




HHV-7 (80.0)
HIV (gag- pol) HHV-7 (U41)


 


 8
81.0
1187   1188




HHV-6A (88.9) HHV-6B (80.0) HHV-7 (77.8)
HIV (gag- pol) HHV-6A (Unknown) HHV-6B (U7) HHV-7 (U57)


 


 9*
80.0*
1189   1190




HHV-7 (84.2) HHV-6A (62.1) HHV-6B (62.1) GBV-C (70.8)
HHV-7 (U95) HHV-6A (U42) HHV-6B (U42) GBV-C (HGV1gp1)


 


10
84.2
1191   1192




HHV-7 (85.0)
HIV (gag- pol) HHV-7 (Unknown)


 


11
81.0
1193   1194




HHV-6A (83.3) HHV-7 (72.0)
HHV-6A (U50) HHV-7 (U40)


 


12
83.3
1195   1196




HHV-6B (80.0) HHV-7 (81.0)
HIV (gag- pol) HHV-6B (DR1) HHV-7 (U4)


 


13
80.0
1197   1198




HHV-7 (81.0)
HIV (gp160, env) HHV-7 (Unknown)


 


14
80.0
1199   1200





HIV (gag- pol)


 


15
83.3
1201   1202




HHV-7 (89.5)
HIV (gag- pol) HHV-7 (U13)


 


16
81.0
1203   1204





HIV (vpr)


 


17
81.8
1205   1206




HHV-7 (84.2)
HIV (gp160, env) HHV-7 (U38)


 


18
81.8
1207   1208




GBV-C (77.3) HHV-6A (85.0) HHV-6B (80.0)
HIV (gp160, env) GBV-C (HGV1 gp1) HHV-6A (U39) HHV-6B (U43)


 


 19*
80.0*
1209   1210




HHV-7 (85.0) HHV-6A (66.7) HHV-6B (69.6) GBV-C (53.1)
HHV-7 (U59) HHV-6A (U27) HHV-6B (U28) GBV-C (HGV1 gp1)


 


20
83.3
1211   1212




HHV-7 (80.0)
HIV (gag, gag-pol) HHV-7 (U4)


 


21
80.0
1213   1214





HIV (gp160, env)


 


22
83.3
1215   1216




GBV-C (77.8) HHV-7 (88.9)
HIV (Unknown) GBV-C (HGV1 gp1) HHV-7 (U41)


 


23
80.0
1217   1218




GBV-C (77.3) HHV-7 (77.3)
HIV (gp160, env) GBV-C (HGV1 gp1) HHV-7 (U57)


 


24
80.0
1219   1220




GBV-C (72.7) HHV-7 (77.3)
HIV (gag- pol) GBV-C (HGV1 gp1) HHV-7 (U86)


 


25
85.0
1221   1222




HHV-6B (82.6)
HIV (gag, gag-pol) HHV-6B (U25)


 


26
80.0
1223   1224




GBV-C (77.8) HHV-6B (80.0) HHV-7 (81.8)
HIV (gag- pol) GBV-C (HGV1 gp1) HHV-6B (U85) HHV-7 (U40)


 


27
80.0
1225   1226




HHV-7 (78.3)
HIV (gag, gag-pol) HHV-7 (U56)


 


28
80.0
1227   1228





HIV (gag- pol)


 


29
80.0
1229   1230




HHV-7 (75.0)
HIV (gp160, env) HHV-7 (U74)


 


30
81.0
1231   1232





HIV (gag- pol)


 


31
83.3
1233   1234




HHV-7 (72.0)
HIV (gag, gag-pol) HHV-7 (U11)


 


32
80.0
1235   1236




HHV-7 (76.2)
HIV (gag, gag-pol) HHV-7 (U60)


 


33
81.0
1237   1238





HIV (vif)


 


34
80.0
1239   1240




HHV-7 (76.2)
HIV (gag, gag-pol) HHV-7 (U60)


 


35
85.0
1241   1242





HIV (gag, gag-pol)


 


36
80.0
1243   1244




GBV-C (76.2)
GBV-C (HGV1 gp1)


 


37
81.0
1245   1246




HHV-7 (85.0)
HIV (Unknown) HHV-7 (U82)


 


38
82.6
1247   1248





HIV (gag, gag-pol)


 


39
81.8
1249   1250





HIV (gag, gag-pol)


 


40
84.2
1251   1252





HIV (nef)


 


41
80.0
1253   1254




HHV-7 (78.3)
HIV (gp160, env) HHV-7 (U30)


 


42
80.0
1255   1256




GBV-C (78.9) HHV-7 (76.2)
HIV (gag, gag-pol) GBV-C (HGV1 gp1) HHV-7 (U60)


 


43
84.2
1257   1258





HIV (gp160, env)


 


44
83.3
1259   1260





HIV (gp160, env)


 


45
83.3
1261   1262




HHV-6B (80.0)
HIV (gag- pol) HHV-6B (U77)


 


46
84.2
1263   1264





HIV (gp160, env)


 


47
80.0
1265   1266





HIV (gp160, env)


 


48
81.8
1267   1268




HHV-7 (75.0)
HIV (gag- pol) HHV-7 (Unknown)


 


49
83.3
1269   1270





HIV (gag, gag-pol)


 


50
80.0
1271   1272




HHV-7 (76.2)
HIV (gag, gag-pol) HHV-7 (U60)





% Homology with asterisk (*) shows the alignment between miRNA and HIV-1 (pNL 4-3)













TABLE 5







Human miRNA Showing mutual Homologies (>=80%) with HIV-1 and with one or more co-infecting viruses


(i.e., GBV-C (>=70%), HHV-6 (>=80%) and HHV-7 (>=70%) and Triplex Stability Index












%
SEQ

Number and triplex


No.
Homology
ID NO:
Sequence Alignment Result
stability index or TSI@















 1
80.0
1273   1274




6/20
30%


 


 2
80.0
1275   1276




6/20
30%


 


 3
80.0
1277   1278




3/20
15%


 


 4
84.2
1279   1280




8/19
42%


 


 5
80.0
1281   1282




4/20
20%


 


 6
82.6
1283   1284




11/23 
47%


 


 7
81.8
1285   1286




6/22
27%


 


 8
81.0
1287   1288




9/21
42  


 


 9*
80.0*
1289   1290




8/20
40%


 


10
84.2
1291   1292




8/19
42%


 


11
81.0
1293   1294




9/21
42%


 


12
83.3
1295   1296




8/18
44%


 


13
80.0
1297   1298




9/20
45%


 


14
80.0
1299   1300




8/20
40%


 


15
83.3
1301   1302




6/18
33%


 


16
81.0
1303   1304




6/21
28%


 


17
81.8
1305   1306




8/22
36%


 


18
81.8
1307   1308




9/22
40%


 


 19*
80.0*
1309   1310




8/20
40%


 


20
83.3
1311   1312




7/18
38%


 


21
80.0
1313   1314




9/20
45%


 


22
83.3
1315   1316




7/18
38%


 


23
80.0
1317   1318




8/20
40%


 


24
80.0
1319   1320




8/20
40%


 


25
85.0
1321   1322




8/20
40%


 


26
80.0
1323   1324




10/20 
50%


 


27
80.0
1325   1326




7/20
35%


 


28
80.0
1327   1328




9/20
45%


 


29
80.0
1329   1330




9/20
45%


 


30
81.0
1331   1332




10/21 
47%


 


31
83.3
1333   1334




7/18
38%


 


32
80.0
1335   1336




6/20
30%


 


33
81.0
1337   1338




9/21
42%


 


34
80.0
1339   1340




6/20
30%


 


35
85.0
1341   1342




8/20
40%


 


36
80.0
1343   1344




—
—


 


37
81.0
1345   1346




11/21 
52%


 


38
82.6
1347   1348




12/23 
52%


 


39
81.8
1349   1350




8/22
36%


 


40
84.2
1351   1352




5/19
26%


 


41
80.0
1353   1354




7/20
35%


 


42
80.0
1355   1356




6/20
30%


 


43
84.2
1357   1358




5/19
26%


 


44
83.3
1359   1360




9/18
50%


 


45
83.3
1361   1362




7/18
38%


 


46
84.2
1363   1364




9/19
47%


 


47
80.0
1365   1366




9/20
45%


 


48
81.8
1367   1368




8/22
36%


 


49
83.3
1369   1370




4/18
22%


 


50
80.0
1371   1372




6/21
28%





% Homology with asterisk (*) shows the alignment between miRNA and HIV-1 (pNL 4-3). The nucleotides highlighted above indicate the modified or replaced nucleotides. These replacements were carried out to increase the triplex forming ability and stability of the miRNAs.

## Claims

1. A method of inhibiting replication of a virus in a target cell in vitro, said method comprising the steps of: (a) introducing into a target cell in a cell culture infected with the virus a microRNA (miRNA) selected from the group consisting of: (i) a nucleotide sequence selected from among SEQ ID NOs: 1290, 1310, 1318, and 1338; (ii) a nucleotide sequence consisting of a full-length complement of SEQ ID NOs: 1290, 1310, 1318, or 1338; and (iii) a 15-25 sequence length oligonucleotide having at least 90% sequence identity to a nucleotide sequence of (i) or (ii), and (b) allowing the miRNA to hybridize with the viral genome.

2. The method of claim 1, wherein the hybridization of step (b) results in the formation of a stable triplex molecule.

3. The method of claim 1, wherein said miRNA is encoded by a recombinant vector.

4. The method of claim 1, wherein said virus is a retrovirus.

5. The method of claim 1, wherein said virus is a lentivirus.

6. The method of claim 1, wherein said virus is HIV.

7. The method of claim 1, wherein said virus is HIV-1.

8. The method of claim 1, wherein said viral genome comprises a proviral or preintegration version of the virus.

9. A method of reducing the level of HIV-1 replication in a target cell in vitro, said method comprising the steps of: (a) introducing into a target cell in a cell culture infected with the virus a microRNA (miRNA) selected from the group consisting of: (i) a nucleotide sequence selected from among SEQ ID NOs: 1290, 1310, 1318, and 1338; (ii) a nucleotide sequence consisting of a full-length complement of SEQ ID NOs: 1290, 1310, 1318, or 1338; and (iii) a 15-25 sequence length oligonucleotide having at least 90% sequence identity with a nucleotide sequence of (i) or (ii), wherein said miRNA additionally is at least 80% complementary to a portion of the HIV-1 genome; and (b) allowing the miRNA to hybridize with the HIV-1 genome or a proviral or preintegration version thereof.

10. The method of claim 9, wherein said hybridization of step (b) results in the formation of a stable triplex molecule.

11. The method according to claim 9, wherein said miRNA is encoded by a recombinant vector.